Merck Expands Bengaluru Facility with €13M Investment in Life Sciences Manufacturing

Merck, a life sciences company, has invested approximately €13 million to expand its manufacturing facility in Jigani, Bengaluru. This investment will strengthen local production of critical chemistry and biology materials for India's growing life sciences sector and customers across the Asia-Pacific region.

The expansion will add biological buffer manufacturing to the site's existing chemistry capabilities, creating an integrated offering for customers in research, diagnostics, biotechnology, and biopharmaceutical manufacturing. This move is part of Merck's 'in-region, for-region' approach to supply and access across key markets.

According to Dhananjay Singh, Managing Director, Life Science business of Merck, India, the country is emerging as an increasingly important hub for life science innovation and manufacturing. Merck is investing in its Jigani site to strengthen regional manufacturing and expand biology and chemistry capabilities across India and the Asia-Pacific region.

The facility will manufacture biological buffers and raw materials for diagnostic applications used in DNA research, cell culture, diagnostics, and drug manufacturing. Production will take place locally under temperature-controlled conditions, helping improve supply reliability, reduce import dependence, and enable faster responses to customer requirements.